Health Minister, Fahrettin Koca stated the following in his statement dated January 29, 2019:
394 patients with a diagnosis of SMA Type 1, who were previously approved, continue to use their medications. 199 of our patients with Type 2 and Type 3 diagnosis have been given drug use approval by our Scientific Commission during this period. We will initiate screening programs with the introduction of domestic diagnostic kits, of which studies are coming to an end, and we will take measures before the disease appears. In order to ensure uninterrupted access to medicines and to ensure that treatment is sustainable, we will ensure the production of the medicine by using a compulsory license.